RESUMEN
In 60-day-old Wistar rats with fetal valproate syndrome, the brain to body weight ratio was higher by 9.4% and activity of dipeptidyl peptidase IV in the serum and cerebrospinal fluid was higher by 18.4 and 40.6%, respectively, than in healthy controls. Activity of prolylendopeptidase in the serum and cerebrospinal fluid in rats with the fetal valproate syndrome did not differ from the control.
Asunto(s)
Anomalías Inducidas por Medicamentos/enzimología , Serina Endopeptidasas/metabolismo , Ácido Valproico/efectos adversos , Anomalías Inducidas por Medicamentos/sangre , Anomalías Inducidas por Medicamentos/líquido cefalorraquídeo , Animales , Dipeptidil Peptidasa 4/sangre , Dipeptidil Peptidasa 4/líquido cefalorraquídeo , Masculino , Prolil Oligopeptidasas , Ratas , Ratas Wistar , Serina Endopeptidasas/sangre , Serina Endopeptidasas/líquido cefalorraquídeo , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
BACKGROUND: Valproic acid (VPA) has been widely used in Chinese patients after craniotomy. Many studies have focused on the influencing factors of VPA serum concentration, but conclusions are sometimes paradoxical. Furthermore, the concentration of VPA in the cerebrospinal fluid (CSF) has been rarely reported. In the present study, VPA CSF concentrations were measured, and the potential factors influencing serum concentration and CSF distribution of VPA were investigated. In addition, the functional relationship between serum and CSF concentration was explored. METHODS: Subjects were patients who underwent craniotomy and were administrated with VPA and had a lumbar puncture. Serum and CSF VPA concentrations were measured by use of the Abbott i1000 system. CYP2C9 (430 C>T, 1075 A>C, 1076 T>C, 1080 C>G), UGT1A6 (541 A>G, 552 A>C), UGT2B7 (211 G>T, 802 C>T), and ABCB1 (1236 C>T, 2677 G>T/A, 3435 C>T) genotypes were determined by direct sequencing. Information, such as age, gender, and height, was collected, and their effect on serum and CSF VPA concentrations was investigated by univariate analysis and multiple linear regression analysis. RESULTS: First, the concomitant use of carbapenems (ß' = -0.422) and UGT1A6 (552 AA â AC) (ß' = -0.249) had a significant negative correlation with the weight-adjusted VPA serum concentration (C:W ratio), whereas CYP2C9 (1075 AA â AC) (ß' = 0.186) and gender (female compared with male) (ß' = 0.322) showed a positive correlation with VPA serum C:W ratio. The coefficient of determination (R) was only 0.348. Second, the relationship between the serum concentration and the CSF square root of the concentration (R = 0.705) had a better linear fit. Third, serum VPA concentration (ß' = 0.810), concomitant use of glycerol fructose (ß' = 0.160), and age (≥65 compared with <65) (ß' = 0.118) showed a positive correlation (R = 0.748) with the variability of square root of the concentration of the CSF. CONCLUSIONS: In Chinese patients, after craniotomy, female patients with 1 or more of CYP2C9 (1075 AC) and UGT1A6 (552 AA) genotypes required a lower VPA dosage compared with male patient. There was a better-fitted linear relationship between VPA serum and the square root of CSF concentrations. CSF VPA concentrations were relatively stable, with only age and the use of glycerol fructose having a small influence.
Asunto(s)
Pueblo Asiatico , Craneotomía/tendencias , Epilepsia/sangre , Epilepsia/líquido cefalorraquídeo , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeo , Anciano , Pueblo Asiatico/genética , Citocromo P-450 CYP2C9/genética , Epilepsia/genética , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
PURPOSE: We established the effects of the antiepileptic drugs (AEDs) carbamazepine (CBZ), topiramate (TPM), and valproic acid (VPA) on the epileptiform activity induced by 4-aminopyridine (4AP) in the rat entorhinal cortex (EC) in an in vitro brain slice preparation. METHODS: Brain slices were obtained from Sprague-Dawley rats (200-250 g). Field and intracellular recordings were made from the EC during bath application of 4AP (50 microm). AEDs, and in some experiments, picrotoxin were bath applied concomitantly. RESULTS: Prolonged (>3 s), ictal-like epileptiform events were abolished by CBZ (50 microm), TPM (50 microm), and VPA (1 mm), whereas shorter (<3 s) interictal-like discharges continued to occur, even at concentrations up to 4-fold as high. gamma-Aminobutyric acid (GABA)(A)-receptor antagonism changed the 4AP-induced activity into recurrent interictal-like events that were not affected by CBZ or TPM, even at the highest concentrations. To establish whether these findings reflected the temporal features of the epileptiform discharges, we tested CBZ and TPM on 4AP-induced epileptiform activity driven by stimuli delivered at 100-, 10-, and 5-s intervals; these AEDs reduced ictal-like responses to stimuli at 100-s intervals at nearly therapeutic concentrations, but did not influence shorter interictal-like events elicited by stimuli delivered every 10 or 5 s. CONCLUSIONS: We conclude that the AED ability to control epileptiform synchronization in vitro depends mainly on activity-dependent characteristics such as discharge duration. Our data are in keeping with clinical evidence indicating that interictal activity is unaffected by AED levels that are effective to stop seizures.
Asunto(s)
Anticonvulsivantes/farmacología , Encéfalo/fisiopatología , Corteza Entorrinal/fisiopatología , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Convulsiones/fisiopatología , 4-Aminopiridina/farmacología , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Animales , Anticonvulsivantes/sangre , Anticonvulsivantes/líquido cefalorraquídeo , Encéfalo/efectos de los fármacos , Carbamazepina/sangre , Carbamazepina/líquido cefalorraquídeo , Carbamazepina/farmacología , Convulsivantes/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Corteza Entorrinal/efectos de los fármacos , Fructosa/análogos & derivados , Fructosa/sangre , Fructosa/líquido cefalorraquídeo , Fructosa/farmacología , Técnicas In Vitro , Masculino , Neuronas/efectos de los fármacos , Neuronas/fisiología , Técnicas de Placa-Clamp , Picrotoxina/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/fisiología , Topiramato , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeo , Ácido Valproico/farmacologíaRESUMEN
Antidepressant drugs affect monoamines and neuropeptides in human cerebrospinal fluid (CSF) and in rodent brain. The purpose of this study was to investigate if also electroconvulsive therapy (ECT) affects these compounds in a similar manner in the CSF of depressed patients. Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and corticotropin-releasing hormone (CRH)-like immunoreactivity (-LI) and neuropeptide Y (NPY)-LI were determined in CSF in six drug resistant patients with major depression. Lumbar puncture was performed at baseline and after completion of eight ECTs. ECT was associated with an increase in NPY-LI (p=0.009) and a decrease in CRH-LI (pAsunto(s)
Hormona Liberadora de Corticotropina/líquido cefalorraquídeo
, Trastorno Depresivo Mayor/líquido cefalorraquídeo
, Trastorno Depresivo Mayor/terapia
, Terapia Electroconvulsiva
, Indoles/líquido cefalorraquídeo
, Neuropéptidos/líquido cefalorraquídeo
, Fragmentos de Péptidos/líquido cefalorraquídeo
, Taquicininas/líquido cefalorraquídeo
, Ácido Valproico/líquido cefalorraquídeo
, Adulto
, Femenino
, Humanos
, Masculino
, Factores de Tiempo
RESUMEN
PURPOSE: Valproic acid (VPA), a widely used antiepileptic, also inhibits histone deacetylase (HDAC), and is undergoing evaluation as an anti-cancer agent. We studied the pharmacokinetics of VPA in the plasma and cerebrospinal fluid (CSF) in a non-human primate model that is highly predictive of human CSF penetration to determine if levels of VPA required to inhibit HDAC in in vivo models can be attained. METHODS: Oral VPA, 75 mg/kg, was administered to four non-human primates. Serial samples of blood (n = 4) and CSF (n = 3) were obtained for pharmacokinetic studies of total and free VPA. Plasma and CSF VPA concentrations were measured using the commercially available Abbott AxSYM VPA assay reagent system (Abbott Laboratories, Abbott Park, IL, USA). The resultant plasma and CSF data were evaluated using pharmacokinetic modeling methods. RESULTS: At a dose of 75 mg/kg, the maximum plasma concentration of VPA was 130.1 +/- 70.6 microg/ml (mean +/- standard deviation) for total drug and 53.3 +/- 44.4 microg/ml for free drug. The mean plasma area under the curve (AUC) for total drug was 680 +/- 233 microg/ml h and for free drug 146 +/- 89 microg/ml hr. The maximum CSF concentration occurred 2-3 h after administration and was 28.2 +/- 18.6 microg/ml. The CSF AUC for VPA was 108 +/- 52 microg/ml h. The CSF penetration of VPA was 12.9 +/- 5.1% for total drug and 57.0 +/- 8.7% for free drug. Disappearance from the plasma followed non-linear kinetics with a V (max) of 321.2 +/- 65.6 microg/kg/min and a K (m) of 17.2 +/- 13.7 mg/l. CONCLUSION: Valproic acid deserves further study for the treatment of CNS tumors given its high CSF penetration after oral dosing coupled with the anti-tumor activity observed in preclinical studies.
Asunto(s)
Antineoplásicos/farmacocinética , Ácido Valproico/farmacocinética , Animales , Antineoplásicos/sangre , Antineoplásicos/líquido cefalorraquídeo , Área Bajo la Curva , Inhibidores Enzimáticos/sangre , Inhibidores Enzimáticos/líquido cefalorraquídeo , Inhibidores Enzimáticos/farmacocinética , Semivida , Inhibidores de Histona Desacetilasas , Macaca mulatta , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
PURPOSE: To quantitatively describe the pharmacokinetics of valproic acid (VPA) in guinea pig serum (total [Cf+b] and free [Cf]), cerebrospinal fluid (CSF) [C]CSF and tears [C]T using a simple kinetic model, and to examine whether [Cf] and [C]CSF can be predicted by [C]T using the resulting pharmacokinetic parameters. METHODS: [Cf+b], [Cf], [C]CSF and [C]T were determined after bolus i.v. injection of 10 or 20 mg/kg VPA using GC/ECNCI/MS. RESULTS: [Cf+b] could be quantitatively described by a two compartment model with linear elimination kinetics. [Cf] was separately analyzed using multi-exponential equations. [C]CSF was analyzed using a simple kinetic model in which the CSF compartment is independently connected with the serum compartment by the apparent diffusion constants (KINCSF and KOUTCSF). [C]T was analyzed using the same simple kinetic model used for [C]CSF. The values of [C]CSF and [Cf] in the steady state can be represented by the following equations; [C]CSF = KINCSF/KOUTCSF x [Cf], [Cf] = KOUT/KINT x [C]T, and indicating that [Cf] and [C]CSF can be predicted by [C]T using the resulting pharmacokinetic parameters. CONCLUSIONS: The measurement of [C]T which can be collected non-invasively and estimated the pharmacokinetic parameters for [Cf], [C]CSF, and [C]T might be a very useful method for TDM of VPA.
Asunto(s)
Anticonvulsivantes/farmacocinética , Monitoreo de Drogas/métodos , Lágrimas/metabolismo , Ácido Valproico/farmacocinética , Animales , Anticonvulsivantes/sangre , Anticonvulsivantes/líquido cefalorraquídeo , Cobayas , Masculino , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
We sought to study the time course of the distribution of valproate (VPA) to subdural cerebrospinal fluid (CSF) in relation to subcutaneous extracellular fluid (ECF) and plasma after a single oral dose and to study the distribution to these three compartments under steady-state conditions. Microdialysis was used to estimate unbound VPA concentrations in subdural CSF and subcutaneous ECF, and blood samples were drawn for estimation of total and unbound VPA plasma concentrations in four patients with drug-resistant partial epilepsy undergoing presurgical evaluation with subdural EEG monitoring. Three patients were given a single oral dose of VPA, and one patient was receiving regular VPA treatment. VPA was analyzed by gas chromatography with flame ionization detection. The distribution of VPA to subdural CSF was rapid (Tmax, 3.5 h in two patients and 5.5 h in one patient) and subject to a minor delay in all three patients compared with that in the subcutaneous tissue ECF (Tmax, 2.5 h in all three patients), which in turn exhibited no evidence of a distribution delay compared with plasma. Subdural CSF levels of VPA were slightly lower than subcutaneous ECF levels (mean ratio, 0.78) and unbound plasma levels (mean ratio, 0.91). VPA rapidly enters the subdural CSF in unbound concentrations marginally lower than those obtained in subcutaneous ECF and plasma. These findings provide a pharmacokinetic rationale for acute administration of VPA. The good correlation between VPA concentrations in subcutaneous ECF and subdural CSF indicates that estimation of unbound VPA concentrations in subcutaneous tissue using microdialysis sampling has the potential to be useful for monitoring purposes.
Asunto(s)
Anticonvulsivantes/farmacocinética , Epilepsias Parciales/metabolismo , Microdiálisis/estadística & datos numéricos , Ácido Valproico/farmacocinética , Administración Oral , Adulto , Anticonvulsivantes/sangre , Anticonvulsivantes/líquido cefalorraquídeo , Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Líquido Cefalorraquídeo/química , Líquido Cefalorraquídeo/metabolismo , Electroencefalografía/estadística & datos numéricos , Epilepsias Parciales/tratamiento farmacológico , Espacio Extracelular/química , Espacio Extracelular/metabolismo , Femenino , Humanos , Masculino , Monitoreo Fisiológico/estadística & datos numéricos , Espacio Subdural/química , Espacio Subdural/metabolismo , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
This report investigates the pharmacokinetics of cytosine arabinoside (Ara-C), methotrexate (MTX), nimustine (ACNU) and valproic acid (VPA) in cerebrospinal fluid (CSF) during CSF perfusion chemotherapy. A 28-year-old Japanese woman with disseminated glioblastoma was, on admission, on a stable oral regimen of prolonged-release VPA tablets (Depakene-R), 400 mg twice a day, for seizure control. Twelve courses of CSF perfusion chemotherapy with Ara-C, MTX, and ACNU were administered. Plasma samples and CSF samples via Ommaya reservoirs were obtained during the eleventh course of treatment. The Ara-C and ACNU concentrations were measured by HPLC. The MTX and VPA concentrations were measured by fluorescence polarization immunoassay. During CSF perfusion chemotherapy, the highest CSF concentrations of Ara-C, MTX, and ACNU were observed at the end of the perfusion and decreased in a monoexponential pattern. The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively. No anticancer drugs were detectable in plasma during CSF perfusion chemotherapy. Before CSF perfusion chemotherapy, the free VPA concentration in plasma was 14.4% of the total VPA concentration. The mean total and free VPA concentrations in plasma were 78.0+/-0.8 and 10.9-0.3 microg/ml, respectively. The free VPA concentrations in plasma and in CSF were of similar values. At the end of perfusion, the lowest free VPA concentration in CSF was 30.3% of that at the initiation of perfusion. The free VPA concentrations in CSF at 3, 7, 23, and 47 h after the end of perfusion were 79.8, 94.5, 100.9, and 100.9% respectively of that at the initiation of perfusion. During CSF perfusion chemotherapy, the ratio of free VPA concentrations to the total VPA in CSF was 86.3+/-6.9%. The VPA concentrations in CSF rapidly decreased during the CSF perfusion but recovered to pre-treatment levels within 7 h.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Neoplasias del Sistema Nervioso Central/líquido cefalorraquídeo , Glioblastoma/líquido cefalorraquídeo , Ácido Valproico/farmacocinética , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/líquido cefalorraquídeo , Neoplasias del Sistema Nervioso Central/tratamiento farmacológico , Neoplasias del Sistema Nervioso Central/radioterapia , Neoplasias del Sistema Nervioso Central/cirugía , Terapia Combinada , Citarabina/administración & dosificación , Citarabina/líquido cefalorraquídeo , Citarabina/farmacocinética , Femenino , Glioblastoma/tratamiento farmacológico , Glioblastoma/radioterapia , Glioblastoma/cirugía , Humanos , Metotrexato/administración & dosificación , Metotrexato/líquido cefalorraquídeo , Metotrexato/farmacocinética , Nimustina/administración & dosificación , Nimustina/líquido cefalorraquídeo , Nimustina/farmacocinética , Ácido Valproico/líquido cefalorraquídeoAsunto(s)
Anticonvulsivantes/farmacocinética , Neoplasias del Sistema Nervioso Central/metabolismo , Glioblastoma/metabolismo , Ácido Valproico/farmacocinética , Adulto , Anticonvulsivantes/líquido cefalorraquídeo , Neoplasias del Sistema Nervioso Central/patología , Quimioterapia del Cáncer por Perfusión Regional , Femenino , Glioblastoma/secundario , Humanos , Ácido Valproico/líquido cefalorraquídeoRESUMEN
Previous experiments suggest the primary route of valproic acid (VPA) removal from the rabbit central nervous system (CNS) is by probenecid-sensitive transporters at the blood-brain barrier but not at the choroid plexus. The purpose of this study was to determine if other transport mechanisms at the choroid plexus played a significant role in the removal of VPA from the CNS. In six rabbits, silicone oil was perfused into both cerebral ventricles and out through the cisterna magna to physically block exchange of VPA between cerebrospinal fluid (CSF) and blood and between brain and CSF. In six control rabbits, perfusion was performed with mock CSF. Both groups received a loading dose followed by continuous intravenous infusion of VPA for 210 min. Ventriculocisternal perfusion with silicone oil had no significant effect on the steady-state brain concentrations or brain-to-plasma concentration ratios of VPA, further confirming that efflux of VPA at the choroid plexus is negligible.
Asunto(s)
Plexo Coroideo/metabolismo , Ácido Valproico/farmacocinética , Animales , Barrera Hematoencefálica/fisiología , Sistema Nervioso Central/metabolismo , Electroencefalografía/efectos de los fármacos , Epitelio/metabolismo , Infusiones Intravenosas , Masculino , Conejos , Distribución Aleatoria , Ácido Valproico/administración & dosificación , Ácido Valproico/líquido cefalorraquídeoRESUMEN
The concentration of valproate was measured in plasma, CSF and brain tissue of patients who underwent resective surgical treatment because of severe temporal lobe epilepsy after pretreatment with either a sustained release formulation of valproate (Depakine Chrono: 5 patients), the conventional formulation of valproate (Depakine: 6 patients) or valpromide (Depamide: 2 patients). With a mean serum value for all 13 patients of 32.3 micrograms/g valproate, the mean brain/serum ratio was 15.1% (SD 6.1%). The valproate concentration of the hippocampus was significantly higher than that of the amygdala, and patients who had the sustained release formulation had significantly higher valproate concentration in the CSF and in the hippocampal formation than those patients who had the conventional valproate. Since a few patients had tumors, whereas others had varying degrees of gliosis, it cannot be ruled out that these differences are the result of different histopathological conditions with related differences in blood-brain barrier functions.
Asunto(s)
Anticonvulsivantes/farmacocinética , Química Encefálica , Ácido Valproico/análogos & derivados , Ácido Valproico/farmacocinética , Adolescente , Adulto , Barrera Hematoencefálica , Encéfalo/cirugía , Epilepsia del Lóbulo Temporal/cirugía , Femenino , Hipocampo/química , Humanos , Masculino , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
Clearance of valproic acid from brain tissue is believed to occur via a carrier-mediated system(s). The present study was designed to determine whether clearance was capacity-limited (saturable) and whether it occurred primarily at the choroid plexus. Ten rabbits were anesthetized with halothane and surgically prepared for ventriculocisternal perfusion. In group 1 (n = 5) valproic acid was added to blue dextran-containing mock cerebrospinal fluid (CSF) to achieve concentrations of 5, 20, 100, and 500 micrograms.ml-1. The mixture was infused through needles in both cerebral ventricles. The purpose of this group was to determine whether over a large range (100x) of valproic acid concentrations, clearance from CSF was capacity limited (saturable). In group 2 (n = 5) valproic acid concentrations were 3, 10, and 30 microgram.ml-1 and infusion was into the left cerebral ventricle only. The purposes of this group were to determine (a) the magnitude of valproic acid clearance for the "clinical" range of valproic acid in CSF (10-30 micrograms.ml-1), and (b) whether clearance of valproic acid was changed by perfusion across a portion of the choroid plexus surface area (group 2) as compared with perfusion across the entire choroid plexus surface area (group 1). In both groups the percent extraction of valproic acid was calculated from the concentration ratio (valproic acid)out/(valproic acid)in corrected for the rate of CSF formation. In group 1 the percent extraction of valproic acid was 93 +/- 2% (mean +/- SD) at 5 micrograms.ml-1 and stabilized within the range of 58-70% (individual values) at the higher inflow concentrations of valproic acid.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Anestesia por Inhalación , Ácido Valproico/líquido cefalorraquídeo , Animales , Encéfalo/irrigación sanguínea , Química Encefálica , Capilares/metabolismo , Ventrículos Cerebrales/metabolismo , Líquido Cefalorraquídeo/metabolismo , Plexo Coroideo/metabolismo , Cisterna Magna/metabolismo , Colorantes , Dextranos , Endotelio Vascular/metabolismo , Tasa de Depuración Metabólica , Conejos , Solubilidad , Ácido Valproico/administración & dosificación , Ácido Valproico/análisis , Ácido Valproico/sangre , Ácido Valproico/farmacocinéticaRESUMEN
The systemic disposition and serum-cerebrospinal fluid (CSF) translocation of valproic acid (VPA) were examined in rats after administration of VPA as a bolus, as a continuous infusion, or with probenecid. VPA in CSF was monitored continuously by in vivo microdialysis. Both prolonged VPA infusion and probenecid pretreatment increased the Km for saturable VPA elimination and decreased intrinsic hepatic clearance, perhaps due to competition of probenecid or accumulated VPA metabolites for glucuronidation or depletion of hepatic UDP-glucuronic acid. The CSF/serum VPA ratio increased rapidly initially, then decreased with time throughout the remainder of the experiment in all three groups. This time- and/or concentration-dependent behavior suggested that the rate of CSF penetration increased disproportionately with increasing serum VPA and could be described by a kinetic model incorporating a concentration-dependent first-order rate constant for VPA influx into CSF. Under all experimental conditions, the VPA efflux from CSF appeared to be saturable; an increase in the Michaelis constant for efflux was observed following probenecid pretreatment and during VPA infusion, suggesting competitive inhibition of transport by probenecid and derived metabolites of VPA, respectively. The mechanisms responsible for asymmetric VPA transport between serum and CSF, in particular the apparent concentration-dependent change in the rate constant governing CSF penetration, remain to be elucidated.
Asunto(s)
Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeo , Animales , Infusiones Intravenosas , Inyecciones Intravenosas , Masculino , Microdiálisis , Modelos Biológicos , Probenecid/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Levels of the antiepileptic drug valproate (VPA) and five of its active metabolites (2-en-VPA, 3-keto-VPA, and 3-,4-, and 5-hydroxy-VPA) were determined by gas chromatography-mass spectrometry in cerebrospinal fluid (CSF) of 15 epileptic children undergoing chronic treatment with VPA. In eight of these children, total and free drug and metabolite concentrations in plasma were also measured. All VPA metabolites present in plasma could also be detected in CSF, although concentrations were substantially lower than those of the parent compound. CSF concentrations of VPA and most of its metabolites were positively correlated with total and free concentrations in plasma. However, concentrations in CSF were always significantly lower than free plasma concentrations, which may be explained by asymmetric transport at the blood-CSF barrier. The data on low CSF levels of VPA metabolites do not exclude the possibility that accumulation of active metabolite(s) may occur in certain brain areas during chronic treatment of epileptic patients with VPA.
Asunto(s)
Epilepsia/líquido cefalorraquídeo , Ácido Valproico/líquido cefalorraquídeo , Niño , Preescolar , Epilepsia/sangre , Epilepsia/tratamiento farmacológico , Humanos , Concentración Osmolar , Factores de Tiempo , Ácido Valproico/sangre , Ácido Valproico/metabolismo , Ácido Valproico/uso terapéuticoRESUMEN
Valproate (VPA) was administered to four rhesus monkeys by constant-rate intravenous infusion for two weeks under controlled conditions. Plasma and CSF samples were collected for a period of 27 hours at 3-hour intervals during steady-state and post-infusion periods. The mean correlation coefficient between total plasma and CSF VPA concentrations was found to be 0.78 +/- 0.09. The CSF VPA levels reflected the changes in free VPA in plasma but the two were not equivalent. Diurnal fluctuations in CSF VPA concentration were similar to those found in plasma but the inter-animal variation was greater in CSF than in plasma.
Asunto(s)
Ritmo Circadiano , Ácido Valproico/líquido cefalorraquídeo , Animales , Macaca mulatta , Ácido Valproico/sangreRESUMEN
Simultaneous cerebrospinal fluid (CSF), total and free plasma valproic acid (VPA) concentrations were measured in 17 patients receiving two weight-adjusted VPA doses as seizure prophylaxis prior to diagnostic myelography or cisternography. Free drug concentrations were similar when measured by equilibrium dialysis (ED) at 37 degrees C for 24 h (Dianorm) or by a novel ultrafiltration (UF) method (EMIT freelevel system 1, SYVA) (ED:2.3-35.5 mg-1; UF:1.3-33.6 mg-1; r = 0.78, P less than 0.002). There was wide variation in total VPA concentration (39-154 mg-1) and in free fraction (ED: 3.3-25.6%; UF: 5.9-24%). Concentration dependent protein binding was not demonstrated. CSF VPA varied between 4.2 and 25.6 mg-1 and was accurately reflected by free plasma VPA concentrations (ED: r = 0.75, P less than 0.005: UF: r = 0.93, P less than 0.001). CSF concentration also correlated with the total plasma VPA (r = 0.76, P less than 0.005). The Emit freelevel system 1 provides a rapid measure of unbound VPA in the plasma which may be suitable for routine clinical use.
Asunto(s)
Ácido Valproico/metabolismo , Adolescente , Adulto , Proteínas Sanguíneas/metabolismo , Diálisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Unión Proteica , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
Concentrations of valproic acid (VPA) and various metabolites were determined in plasma, cerebrospinal fluid and discrete brain areas in dogs after acute treatment with VPA as well as in rats during prolonged constant-rate application of the drug via osmotic minipumps. Highly sensitive gas chromatograph-mass spectrometer-computer methods were used for drug and metabolite analysis. Of several VPA metabolites present in plasma of dogs and rats only one could be found in the brain of both species, 2-propyl-2-pentenoic acid (2-en-VPA). Distribution of VPA and 2-en-VPA in the brain was rather homogenous, but during prolonged treatment accumulation of 2-en-VPA was found to occur in some brain regions. Determination of anticonvulsant potency of 2-en-VPA in mice indicated that the compound is about 1.3 times more potent than the parent drug when calculation is based on whole-brain concentrations. Administration of 2-en-VPA in a dog showed that pharmacokinetics of this substance are similar to those of VPA, although plasma protein binding of 2-en-VPA (97%) is much higher than of VPA. The results suggest that 2-en-VPA may contribute significantly to the anticonvulsant effect of (chronic) treatment with VPA.
Asunto(s)
Encéfalo/metabolismo , Ácidos Grasos Monoinsaturados , Ácido Valproico/sangre , Ácido Valproico/farmacología , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/farmacología , Química Encefálica/efectos de los fármacos , Perros , Relación Dosis-Respuesta a Droga , Ácidos Grasos Insaturados/administración & dosificación , Ácidos Grasos Insaturados/análisis , Ácidos Grasos Insaturados/sangre , Femenino , Masculino , Ratones , Ratones Endogámicos , Ratas , Ratas Endogámicas , Factores de Tiempo , Ácido Valproico/líquido cefalorraquídeoRESUMEN
Valproic acid (VPA) was determined by EMIT assay in plasma, tears, saliva, and cerebrospinal fluid (CSF) of patients with epilepsy. Closer correlation was shown between tear/plasma and tear/CSF ratios than between saliva/plasma and saliva/CSF ratios. The VPA CSF/serum ratio was in good agreement with data in the literature. Salivary levels were extremely erratic, while those for tears were much more reliable. Determination of VPA in tears is therefore the best method of studying the VPA free fraction in those cases in which investigations of protein binding of the drug are necessary.